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1. Introduction 
Steroids play a vital role in human physiology and medicine. Glucocorticoids have 
dominated the class of anti-inflammatory agents quite successfully over other drugs since 
their introduction to dermatology more than fifty years ago. Later they have been developed 
both as topical and systemic anti-inflammatory agents. From studies it has been found that 
glucocorticoids normally release their anti-inflammatory effects mainly through the 
modulation of the cytosolic glucocorticoid receptor (GR) at the genomic level [1, 2]. The 
activated glucocorticoid-GR complex formed via binding of glucocorticoid with the GR in 
the cytoplasm, migrates to the nucleus, where it upregulates the expression of anti-
inflammatory proteins and repress the expression of pro-inflammatory proteins. In some 
recent work, it has been reported that the activated glucocorticoid-GR complex has also 
been found to initiate nongenomic effects like inhibition of vasodilation, vascular 
permeability and migration of leukocytes [1, 3]. Glucocorticoids also mediate anti-
inflammatory activity through membrane-bound GR-mediated nongenomic effects and also 
through direct non specific interaction with cellular membranes [3, 4]. Since GR is involved 
in a plethora of signalling pathways, more than 5000 genes are expressed or suppressed 
following glucocorticoid exposure [4, 5]. Therefore long term use or high dosages of 
glucocorticoids could result in adverse drug reactions (ADRs) like increased Intraocular 
Pressure (IOP) [6, 7] in ocular therapeutics. Glucocorticoids- induced ocular hypertension is 
of great concern in ophthalmic therapeutics as it can lead to secondary iatrogenic open-angle 
glaucoma. Glaucoma is a group of eye diseases characterized by progressive optic nerve 
cupping with visual field loss leading to bilateral blindness. It has been reported that 
glaucoma is estimated to affect more than 50 million people worldwide as defined by the 
World Health Organization (WHO) [8].  
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However, the use of corticosteroids has become more and more restricted and unacceptable 
because most of these agents are found to be associated with severe side effects, including 
percutaneous absorption and cutaneous atrophy [9]. Also allergic contact dermatitis is an 
unexpected adverse effect in most of these corticosteroids. On the other hand because of 
their high efficacy, their use is inevitable to give them the status of life saving drugs. The 
severe side effects associated with these glucocorticoids, has led to the pharmaceutical 
industry to make a productive effort towards the introduction of new generation of topical 
corticosteroids with specific substituents in their parent molecules to make them safer in 
comparison to the old generation glucocorticoids [10]. 
The effectiveness of hydrocortisone was first demonstrated by Sulzberger and Witten 
during 1950 [11] and soon after the new and more effective fluorinated hydrocortisones 
were introduced in the market during 1960 [12]. Further R&D works on these 
glucocorticoids led to introduction of super potent corticosteroids in the 1970s and 1980s. 
Cornell and Stoughton [13] had proposed a potency rating of these topically applied 
glucocorticoids in 1984, based primarily on the vasoconstrictor assay or skin-blanching of 
corticosteroid preparations. Again based upon the consensus of the United States 
Pharmacopoeia (USP) Dermatology Advisory Panel, a classification of the potency ranking 
for these glucocorticoids had been done as low, medium, high and very high [14]. New 
generation of glucocorticoids do not cause much cutaneous atrophy or systemic absorption 
in human body. Molecular configuration of these new corticosteroids tends to display a 
rapidly declining concentration gradient in the skin. Many of these new generation 
glucocorticoids are developed through the concept of prodrugs – a tool for improving 
physiochemical, biopharmaceutical or pharmacokinetic properties of pharmacologically 
active agents. Thus prodrugs are bioreversible derivatives of drug molecules that undergo 
an enzymatic or chemical transformation in vivo to release the active parent drug, which 
could then exert the desired pharmacological effect. These new generation glucocorticoids 
primarily act in the top layers of the skin where the most important mediators of the 
inflammatory reactions are [10, 14] found. 
As for these new generation glucocorticoids, the action in the deeper layer is considerably 
diminished making them having less systemic side effects [14]. European and North 
American based clinical studies have shown that the new generation corticosteroids with 
their improved risk- benefit ratio are as effective as products currently available in the 
market [15]. These new generation glucocorticoids are highly effective in treating plethora of 
disease including psoriasis, allergies, asthma, rheumatoid arthritis and lupus [2-8, 14,15].  
Again the application of anti-inflammatory agents in ophthalmic therapeutic is a 
challenging task because of severe complications arising out of the currently used anti-
inflammatory agents. The eye is vulnerable to damage from low level of intraocular 
inflammation. The blood-aqueous and blood-retinal barriers generally limit penetration of 
protein and cells from peripheral circulation, while regulatory molecules and cells in the eye 
actively suppress immunological responses [16]. The fact that ocular inflammatory 
conditions and surgical trauma induce changes in the blood- aqueous and blood-retinal 
barriers [16-18], due to which immune cells and mediators of inflammation could enter the 
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eye, resulting in the development of symptoms of ocular inflammation such as redness, 
pain, swelling and itching [19]. Ocular inflammation is a serious problem, negligence of 
which may lead to temporary or permanent blindness [20].  
Clinical studies suggest that topical glucocorticoids are effective in the management of 
anterior segment inflammation. They impart a number of potent anti-inflammatory effects 
[21]. They are found to suppress cellular infiltration, capillary dilution, proliferation of 
fibroblasts, collagen deposition leading to scar formation; they also stabilize intracellular 
and extracellular membranes. Glucocorticoids increase the synthesis of lipocortins which 
block phospholipase A2 and also inhibit Histamine (A) synthesis in mast cells. A critical step in 
the inflammatory cascade is the inhibition of phospholipase A2 that inhibits the transformation 
of Phospholipids (B) to Arachidonic acid (C). Glucocorticoids are also found to increase the 
enzyme histaminase and modulate transcription factors present in mast cell nuclei [21, 22]. 
The formation of cataract is also one of the severe adverse drug reactions (ADRs) associated 
with glucocorticoids when used for ocular problems. 
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It has been reported by Manabe et al [23] that the mechanism of steroid-induced cataract 
formation is chemically based and possibly not related to the downstream effects of 
glucocorticoid receptor (GR) activation. At present the most accepted hypothesis of this 
mechanism is likely to involve non-enzymatic formation of Schiff base intermediates 
between the steroid C-20 ketone group and nucleophilic groups such as  -amino groups of 
lysine residues of proteins (Figure 1). Schiff base formation is followed by a Heyns 
rearrangement [23] involving the nearby C-21 hydroxyl group of the glucocorticoid 
molecule furnishing stable amine-linked adducts. This covalent binding results in the 
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destabilization of the protein structure allowing further oxidation leading to steroid-induced 
cataract formation [23]. 
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Figure 1. Mechanism of steroid-induced cataract formation due to the synthesis of the stable steroid- 
amine adduct between the C-20 carbonyl group of glucocorticoids and nucleophilic group such as - 
amino groups of lysine residues of proteins via formation Schiff Base  
R&D work in understanding the mechanism of action of steroids, both for their anti-
inflammatory effects and adverse drug reactions (ADRs) has lead to the development new 
generation glucocorticoids mainly through prodrug design approach to find use in treating 
plethora of diseases as mentioned earlier. All these new generation glucocorticoids are not 
designed for ophthalmic therapeutics. Hence a real breakthrough in the field of ophthalmic 
therapeutic could be achieved only by specifically designing new drug entities to 
incorporate the eye targeting possibility into their chemical structure [24,25]. Chemical 
Delivery Systems (CDSs) and Retrometabolic drug design principles have led to 
development of a new but unique class of glucocorticoids which are safe and effective in 
treating a wide variety of ocular inflammatory conditions including giant papillary 
conjunctivitis, seasonal allergic conjunctivitis, and uveities as well as in the treatment of 
ocular inflammation and pain following cataract surgery. This new and unique class of 
glucocorticoids are now known as soft glucocorticoids which are associated with highly 
minimized ADRs to justify terming them as `soft drugs’ [24, 26]. 
It is pertinent to note that, this important drug design based on Chemical Delivery Systems 
(CDSs) and Soft drug (SD) approaches integrate the specific pharmacological, metabolic, 
and targeting requirements for ophthalmic therapeutics. .A number of glucocorticoid soft 
drugs and soft  -blockers have been developed this way for clinical trials. Their potential is 
already documented by the results obtained with several soft drugs designed within this 
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framework. Glucocorticoid soft drugs such as Loteprednol Etabonate, and Etiprednol 
Dicloacetate and  -blockers such as Betaxoxime, and Adaprolol are some of the new 
chemical entities developed as soft drugs for ocular applications. Besides, many of these soft 
drugs have already reached the clinical development phase in various ophthalmic areas and 
one of them Loteprednol Etabonate has already been marketed [ 24]. Herein we review the 
important aspects of the development of new generation glucocorticoids through prodrug 
approach with special reference to the development of the first and second generation 
glucocorticoid soft drugs by the application chemical delivery systems (CDSs) and 
retrometabolic drug design approaches towards ophthalmic therapeutics. A few examples 
of soft ocular  –blockers have also been cited to know more about the retrometabolic drug 
design approach in depth as have been put forwarded by Bodor and his co-workers (24). 
2. New generation glucocorticoids: Prodrugs 
As discussed earlier several numbers of new entities of glucocorticoids have been developed 
during the last two decades. Many of them are already in market for their high efficacy and 
less systemic side effects. These new generation corticosteroids were developed with 
modifications made in the basic glucocorticoid molecules, viz., Betamethasone 1 or 
Dexamethasone 2 extensively used during early stage of glucocorticoids therapy. The main 
object of synthesizing these modified glucocorticoids was to get better skin penetration, 
slower enzyme degradation, and greater affinity for cytosol receptors [5]. 
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Even then in some cases it was observed that the changes that increased potency, also led 
sometimes to more systemic side effects. As per clinical investigations by various workers, 
these new generation glucocorticoids have been found to act via hepatic or extra hepatic 
biotransformation. These results in lesser systemic side effects and hence are much safer 
drugs to be used specially by adults and non- erythrodermic patients. However, while 
systemic side effects are of concern, cutaneous side effects are generally common involving 
problems such as striae formation, atrophy, purpura, peri-oral dermatitis, steroid rosacea, 
hypertrichosis and steroid acne [2,6]. Most of the side effects associated even with these new 
generation glucocorticoids are basically related to the duration and potency of the 
application, the manner of application, the presence of penetration-enhancing substances 
and the state of skin barrier. Besides these, the anatomic site and the age of the patient could 
also adversely influence the side effect profile [2, 6]. In both drug discovery and 
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development, prodrug design approach helped to maximize the amount of an active drug to 
reach its target through changing the physicochemical, pharmacokinetics or 
biopharmaceutical properties of the drug. Therefore the term prodrug refers to a 
pharmacologically inactive compound which is converted to an active drug by metabolic 
biotransformation which may occur prior, during or after absorption or at specific target 
sites within the body because of their specific molecular configurations [28-30]. The labile 
`prodrug’ corticosteroids such as 17-Prednicarbate, Alclometasone, Methylprednisolone 
aceponate, Fluticasone Propionate and Fluocortin butylester are some of these new 
generation glucocorticoids which are developed through prodrug approach [2,6]. Based on 
the molecular configuration of these new generation glucocorticoids, they are classified into 
several categories [Table1] [2, 6]. 
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Table 1. Classification of new generation glucocorticoids on the basis of their molecular configurations 
Chemical stability is another criteria for classification of these new generation corticosteroids. 
Based on this, most of these newer drugs can be regarded as prodrugs because immediately 
after application to the system, they undergo metabolization and acyl-exchanges to form the 
active molecule to fight the ailment in the system. As mentioned earlier, all these 
glucocorticoids have been developed through prodrugs design approach in order to maximize 
the amount of an active drug reaching its target through changing the physicochemical, 
biopharmaceutical or pharmacokinetic properties of drugs. Prodrugs are bioreversible 
derivatives of drug molecules that undergo an enzymatic or chemical transformation in vivo to 
release the active parent drug, which can then exert the desired pharmacological effect [28-30]. 
Most of the new generation corticosteroids have been found belonging to the class of molecules 
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having high potency. By introducing various substituents at different positions, changes or 
modifications were made on the parent hydrocortisone molecules, such as Betamethasone (1) 
and Dexamethasone (2) in order to get better skin penetration, slower enzymatic degradation 
and greater affinity for the cytosol receptor for these molecules to reduce or eliminate their 
systemic side effects [6]. The systemic side effects of these new corticosteroids are reduced due 
to rapid biotransformation while applying them for treatment of atopic dermatitis. However it 
is pertinent to note that there are still risks of having potential hypothalamus and pituitary axis 
(HPA) suppression with some of these new generation glucocorticoids while treating young 
children and erythrodermic patients. Clinical safety has been demonstrated in most of these 
newer corticosteroids with restricted duration of treatment up to six weeks [2, 6]. Even then skin 
atropy and some telangiectasia have been observed in some patients. A large number of reports 
of contact allergic reactions associated with these new generation glucocorticoids were still of 
great concern. To explain the increased allergenicity, data from clinical studies and literature 
were reviewed to define precisely some of the more important groups of cross-reacting 
molecules [31]. Table2 represents the various allergy groups of these newer glucocorticoids 
based on their molecular structures and configurations. Clinical studies have revealed that 
Tixocortol pivalate (19) has been identified as a good screening agent for the Group A [32]. 
Budesonide (3) is infact a 1:1 mixture of two diasteriomers (R- and S- isomer). The R-isomer has 
been found to be a marker for the Group B while the S-isomer for the Group D. Glucocorticoid 
members of Group C cause minimized contact sensitivity and do not cross react with other 
groups. As shown in Table2, Group D has been divided in two sub-groups D1 and D2 based on 
recent studies [2, 33] with respect to their mode of substitutions.  
 
Group Molecular configuration Characteristics of substituent
A Hydrocortisone (12) type 
No substitution in D ring, except a short chain ester on C-17 or C-
21 or a thioester on C-21
B Triamcinolone (13 ) type C-16,C-17-cis-ketal or –diol structure 
C 
Betamethasone (1) type C-16 methyl substitution, no side chain on C-17; possible side 
chain at C-21. Fluocortin Butylester (4)
D Hydrocortisone-17α-butyrate(14) type
Long chain ester at C-17 and/or C-21 with or without C-16 methyl 
substitution.
D1 
Betamethasone 
Dipropionate(15)
Long chain ester at C-17 and/or C-21 with C-16 methyl 
substitution; halogen substituent in ring B 
Betamethasone17α-Valerate 
(16)
Clobetasol 17α -Propionate 
(17)
Mometasone Furoate (10)
Fluticasone Propionate (11)
D2 
Hydrocortisone-17α-
butyrate(14)
Long chain ester at C-17; possibly a side chain at C-21; no methyl 
substitution at C-16 and no halogen substituent in ring B. 
Hydrocortisone 17α-
Valerate (18)
17-Prednicarbate (9)
Methylprednisolone 
Aceponate (5)
Table 2. Allergy Groups of new generation corticosteroids based on their molecular structures and 
configurations  
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To the Group D1, belong not only the old generation glucocorticoid molecules like 
Betamethasone dipropionate (15), Betamethasone-17α-valerate (16) and Clobetasol 17α 
propionate (17) but also new generation corticosteroids such as Mometasone furoate (10) and 
Fluticasone propionate (11). These glucocorticoids are found to possess very less systemic side 
effects and so can be used safely even in case of patients who are allergic to other 
corticosteroids. To the Group D2 belong Hydrocortisone-17α- valerate (18) and Hydrocortisone -
17α-butyrate (14 ) as well as the labile new generation glucocorticoids like 17-Prednicarbate (9) 
and Methylprednisolone Aceponate (5). They are sometimes found to cause allergic reactions.  
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S-isomer of Budesonide (3) is the marker for this Group D2, but they can cross react with the 
Group A. Table 3 illustrates the safety profile, potency , side effects and allergy groups of 
some of the new generation glucocorticoids along with their manufactures. 
 
 
Product Manufacturer Safety profile Potency Side effect Allergygroup 
Budesonide(3) Astra, Entcort 
A Stable 
asymmetric 
acetonide 
undergoing rapid 
biotransformation 
in liver with less 
systemic side effects
High 
potency
May be problem 
with contact 
sensitivity 
B 
Mometasone 
Furoate (10) 
Schering-Plough, 
Elocom 
A stable chlorinated 
topical 
glucocorticoid with 
low penetration 
with high biliary 
excretion, and also 
low resorption in 
the circulation with 
fast 
biotransformation 
in the liver resulting 
in rare local 
systemic side effect.
High 
potency
Very rare 
contact 
hypersensitivity 
D1 
Fluocortin 
butylester(4) 
Schering Corp.-
Essex, Varlane 
Biotransformation 
into the non- active 
fluocortolone-21-
acid in skin. 
Medium 
potency
Rare contact 
hyper-
sensitivity 
C 
Alclometasone 
dipropionate(6) 
Schering-Plough, 
Aclovate, Glaxo- -
welcome 
A labile prodrug 
metabolizing to 
inactive compound
High 
potency
Occasional 
Contact hyper-
sensitivity 
D2 
17-Prednicarbate( 9)
Hoechst- 
Roussel,Dermatop 
Emollient 
A labile prodrug 
glucocorticoid, 
converting to 
prednisolone in the 
skin 
High 
potency
Contact hyper-
sensitivity is 
observed. Also 
can cross-react 
with the Group 
A 
D2 
Methylprednisolone 
aceponate(5) 
Schering Corp. 
Essex, Advantan 
A labile prodrug. 
Get transformed 
into methyl 
prednisolone in the 
skin and into 
nonactive 
derivatives in the 
liver 
High 
potency
Contact hyper-
sensitivity is not 
rare 
D2 
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Fluticasone 
propionate (11) 
Cutivate, Glaxo 
Wellcome 
A fluorinated 
topical 
glucocorticoid. 
Readily 
metabolized in the 
liver resulting in a 
locally potent sterid 
drug with a low 
HPA inhibitory 
potency 
High 
potency
Contact hyper-
sensitivity is 
very rare 
D1 
Beclomethasone(7) 
Schwitz Biotech, 
Havione 
Farmaciencies, 
Portugal 
A chlorinated 
topical 
corticosteroid. 
Readily 
metabolized in the 
liver resulting in a 
locally potent 
steroid with a low 
HPA inhibitory 
potency 
High 
potency
Contact hyper-
sensitivity is 
very rare 
D1 
Cyclesonide (8) 
Brand Name: 
Alvesco, Taj 
Pharmaceuticals 
Ltd. India 
A triamcinolone 
type Gluco-
corticoid with low 
HPA inhibitory 
potency 
High 
Potency
Contact hyper-
sensitivity is 
rare 
D1 
Table 3. Some of the marketed new generation glucocorticoids and their allergy groups: 
Continuous efforts are still being still sought after by pharmaceutical companies worldwide 
to develop and market more and more safer glucocorticoids as anti-inflammatory agents, 
because clinical investigations on some already marketed newer glucocorticoids have 
revealed that many of them are still prone to cause allergic reactions and other systemic side 
effects specially on prolonged use. However, glucocorticoids are still regarded as life saving 
drugs dominating over the other anti-inflammatory agents for the treatment of a number of 
diseases including psoriasis, allergies, acute asthma, rheumatoid arthritis and lupus.  
Eye–targeted Chemical Delivery Systems (CDSs) and retrometabolic drug design: Soft -Blockers 
and Soft Glucocorticoids 
Soft corticosteroids or Soft glucocorticoids can be termed as a unique class of new 
generation glucocorticoids that are designed specifically for ophthalmic therapeutics [24-
27]. The new generation glucocorticoids developed by prodrug approach as described 
earlier have brought revolution in treating a plethora of disease including psoriasis, 
allergies, asthma, rheumatoid arthritis and lupus because of their minimized systemic side 
effects. However, these new generation glucocorticoids are still not useful for ophthalmic 
applications due to their association with adverse drug reactions (ADRs) including 
elevation of intraocular pressure (IOP) and steroid-induced cataract formation [23] in 
ophthalmic applications. For the therapeutic treatment of most of ocular problems, topical 
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administration undoubtedly seems preferred mode, because for systemically administered 
drugs, only a very small fraction of the total dose will reach the eye from the general 
circulatory system. Even distribution for this fraction to the inside of the eye is further 
hindered by the blood-retinal barrier (BRB), which is almost as effective as blood-brain 
barrier (BBB) in restricting the passage of xenobiotics from the blood stream [34]. Therefore 
despite its apparent accessibility, the eye, in fact, is well protected against the absorption of 
foreign materials, including drug molecules, by the eyelids, by flow of tears, and also by 
the permeability barriers imposed by the cornea on one side and the blood-retinal barrier 
on the other side as mentioned above [24]. Because of this a significant portion of the 
applied drug is absorbed through nasolacrimal duct and the mucosal membranes of the 
nasal, oropharyngeal, and gastrointestinal tract to pass to the system. It has been found 
that no more than 2% of medication introduced topically to the eye is adsorbed [35-37]. 
Again clinical studies by various workers reveal that the main biological barrier for 
penetration to the eye is represented by the cornea. The relatively lipophilic corneal 
epithelium tissue having low porosity and high tortuosity due to tight annular junctions, 
is the primary barrier for hydrophilic drugs, where as the middle stromal layer 
consisting mainly of water interspersed with collagen fibrils( major thickness of cornea), 
is the main barrier for the lipophilic drugs [38-41]. All these facts result not only in a low 
net eye drug delivery, but also in substantial systemic availability of ophthalmic drugs after  
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topical administration giving systemic side effects [42]. Moreover as mentioned earlier, 
existing ophthalmic drugs are actually not developed for ocular applications, they were 
intended for other therapeutic areas which were later converted to ocular applications 
following their high efficacy. This further has decreased the likelihood of achieving eye-
specific delivery along with reduced systemic side effects. In view of this, various drug 
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design approaches have been tried to eliminate the problems of low ocular delivery and 
potential for substantial systemic side effects [6, 43]. It has been found that prodrug 
approach here had some limitations. Prodrugs are pharmacologically not active (or may be 
weakly active) compounds that results from transient chemical modifications of biologically 
active species, so that they are metabolically transformed into effective drugs following 
administration [28-30, 44-47]. Compared with the original structures, prodrug structures 
incorporate chemical modifications to get improvement in some deficient physiological 
properties, such as membrane permeability or water solubility or to overcome some other 
problems like rapid elimination, bad taste, a formulation difficulty etc. After administration, 
the prodrug because of its improved characteristics, is more systemically or locally available 
than the parent drug. However the prodrug must undergo chemical or biochemical 
conversion to the active form before exerting its biological effect. Some of the marketed 
ophthalmic prodrugs include Dipivefrine (21)-the dipivalate ester prodrug of epinephrine 
(20), latanoprost (22) and travoprost (23) -isopropyl ester prodrugs that are prostaglandin 
F2α (24) analogs [24]. 
Retrometabolic Drug Design: 
Because of the adverse drug reactions (ADRs) associated even with the new generation 
glucocorticoids in ocular treatment, the real breakthrough in the area of ophthalmic 
therapeutics could be achieved only by specifically designing new drugs with their 
ophthalmic applications in mind, so that the possibility of eye targeting with reduced 
systemic side effects is already incorporated in their chemical structures. In an effort to 
minimize ADRs and other complicacies associated with glucocorticoids, Bodor and his 
colleagues for the first time have developed the concept of retrometabolic drug design for 
ophthalmic therapeutics to introduce a new and unique class of glucocorticoids now known 
as soft corticosteroids or soft glucocorticoids that helped in developing glucocorticoid soft 
drugs for ophthalmic use [24, 48-50]. Soft -blockers are also falling in this soft drug 
category. The concept of soft drugs has been originated from the pioneer work of Prof. N 
Bodor and his co-workers at the Center for Drug Discovery, University of Florida, Health 
Science Center, Gainesville, FL 32610-0497, USA [24, 48-50]. The possibility of developing 
these soft drugs has been extensively studied along the lines of retro- metabolic drug design 
for two important classes of ophthalmic drugs, - blockers and glucocorticoids [24]. The 
underlying principle of retrometabolic drug design involves synthesizing analogs of lead 
molecules or reference molecules, starting from one of the known inactive metabolites of 
that lead compound. The inactive metabolite is then converted to an isosteric or isoelectronic 
analog with structural modifications designed for a rapid and predictable metabolism back 
to the original inactive metabolite after exerting the desired therapeutic effect at the site 
(Figure 2) [24, 26]. These analogs or soft drugs were predicted to have therapeutic potential 
similar to that of the lead compound, but because of the structural modifications provided 
by the design, any active drug remaining after attainment of the therapeutic effect would be 
metabolically deactivated, thus reducing adverse drug reactions (ADRs) [24, 26, 48-51]. 
According to Prof Bodor, in developing soft drugs the goal is not to avoid metabolism but 
rather to control and direct it. Inclusion of a metabolically sensitive moiety into the parent 
drug molecule can make possible the design and prediction of the major metabolic pathway 
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preventing the formation of undesired toxic, active, or high-energy intermediates. It is 
desired that, If possible, inactivation should take place as the result of a single, low- energy 
and high- capacity step that gives the inactive species subject to rapid elimination. Most 
critical metabolic pathways in a biological system are mediated by oxygenases, a consequence 
of the fact that the normal reaction of an organism to a foreign material is to burn it up as 
food [52]. However oxygenases exhibit not only interspecies, but also inter individual and are 
subject to inhibition and induction (24) and because the rates of hepatic mono-oxygenases 
reactions are at least two orders of magnitude lower than the slowest of the other enzymatic 
reactions [53,54], it is usually desirable to avoid oxidative pathways as well as these slow, 
easily saturable oxidases. In view of this, the design of soft drugs must be based on moieties 
activated by hydrolytic enzymes. Rapid metabolism could be more reliably performed by 
these ubiquitously distributed esterases. Bodor et al (26) suggested that it is desirable not to 
rely exclusively on metabolism by organs such as kidney or liver to have an additional 
advantage because blood flow and enzyme activities in these organs can be fatally damaged 
in critically ill patients. However, the increase in the therapeutic index can only be achieved 
if the drug is stable enough to reach its receptor site to deliver the desired effect, and any 
free drug remaining thereafter should be metabolized to minimize ADRs [24]. 
 
 
Figure 2. Retrometabolic drug design approach: Synthesis of new lead molecules (Soft drugs) based on 
an inactive metabolite of an original lead molecule  
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Figure 3. Site- and Stereospecific delivery of -adrenergic antagonists to the eye through sequential 
activation of their oximes and alkyl oximes.  
Soft- -Blockers: 
As because soft drug design is a general concept, topically applied soft drugs that show 
local activity with reduced systemic side effects could become potential therapeutics for any 
ocular diseases [24]. During the last three decades, Bodor and his colleagues have applied 
retrometabolic drug design to a variety of therapeutic agents such as - blockers, 
antimicrobials, analgesics, and acetyl cholinesterase (ACE) inhibitors and were successful in 
developing retrometabolically designed compounds with market potential. As for example, 
in addition to the oxime or methoxime  -blocker analogs, the development of soft  -
blockers could represent another possible route toward improved and safer antiglaucoma 
agents [54-62]. Several oxime and methoxime analogs of known  -Adrenergic blockers such 
as Alprenolol (25), Betaxolol (26)l, Timolol (27) etc. were synthesized from their respective 
ketone derivatives, viz., Alprenolone (28), Betaxolone (29), Timolone (30) and studied 
clinically [54-62]. They are potential drugs which have been developed applying general 
retrometabolic drug design principle and can be recognized as site-specific enzymatic 
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chemical delivery systems (CDSs) [54-62]. In these compounds, a  -amino oxime or 
alkyloxime function replaces the corresponding  -amino alcohol pharmacore part of the 
original molecules (Figure 3). These oxime or alkyloxime derivatives (31) are found to exist 
in Z (syn) or E (anti) configuration. They are hydrolyzed within the eye by enzymes located 
in the iris-cillary body and subsequently again by reductive enzymes present there 
producing only the active S- (-) stereoisomeric alcohol (32) of the corresponding -blockers 
[54]. For aryl  -amino alcohol-type  -adrenergic agonists and antagonists, most of the 
activity has been known to be  
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Figure 4. Inactive Metabolite-based Soft Drug Design: Comparison of the structure and metabolism of 
the soft  -blocker Adaprolol (23) with that of the traditional  -blocker Metoprolol(24).  
present with the S- (-) stereoisomer [63-65], possibly because this isomer allows better 
interaction of all three important functionalities (aromatic, amino and  -hydroxyl moieties) 
with the  -adrenoceptor. In fact these oxime and alkyloxime derivatives have been found to 
exhibit significant intraocular pressure (IOP) lowering activity, but even their intravenous 
administration did not produce the active  -blocker metabolically; as a result they are void 
of any cardiovascular activity, which has been found to be a major drawback of classical 
antiglaucoma agents [26].  
According to Bodor and his team [24], the oxime-type CDS approach clearly demonstrates 
the site- specific or site-enhanced drug delivery through sequential, multi-step enzymatic 
and/or chemical transformations through a targetor moiety that is converted into a 
biologically active function by enzymatic reactions which take place primarily at the site of 
action as a result of differential distribution of some enzymes found in the eye [24]. 
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Again as Prof. Bodor and his team suggest [24,26], soft drugs (SDs) represent a different, 
conceptually opposite targeting concept; whereas eye-targeting CDSs, represented here by 
the above discussed oxime analogs, are inactive compounds designed to achieve the 
targeted effects via a multi-step activation process by enzymes found at their intended site of 
action. However soft drugs represented by -blockers or glucocorticoids are active 
compounds designed to achieve the targeted effects via a single-step inactivation process 
involving enzymes found ubiquitously in the systemic circulation. Because in this class, 
inactive metabolite based soft drugs can be achieved introducing the hydrolytically sensitive 
functionality at a flexible pharmacophore region, there is considerable freedom for 
structural modifications. As a result, transport and metabolism properties are easier to 
control. From the various soft -blockers developed along these lines by Bodor and 
Buchwald [24], Adaprolol (33), an adamantane ethyl ester was selected as a potential 
candidate for a new topical antiglaucoma agent [24 ]. The metabolism of the well-known  -
blocker Metoprolol (34) has been compared with that of the soft  -blocker Adaprolol which 
has been designed starting from one of Metoprolol`s inactive acid metabolite (35), viz., 
phenyl acetic acid (Figure 4). Its other metabolites include -hydroxymetoprolol (36) and O-
Dimethylmetoprolol (37) both of which are active. Another inactive metabolite includes the 
acid derivative 38. Adaprolol was chosen because of the fact that if membrane transport 
(lipophilicity) and relative stability are important for pharmacological activity as they are 
needed to achieve right corneal permeability, then the ester goup should be relatively 
lipophilic and should provide ester stability [66-70]. In clinical trials Adaprolol (33) indeed 
produced prolonged and significant IOP-reduction while hydrolyzed relatively fast [67, 68]. 
Therefore, it was possible to separate local activity from undesired systemic cardiovascular 
or pulmonary activity, a characteristic highly desirable in development of antiglaucoma 
therapy [24]. Adaprolol (33) could be now a potent antiglaucoma soft  -blocker to replace 
the traditional  -blocker Metoprolol (34). Further clinical studies confirmed that Adaprolol 
is not only effective in reducing intraocular pressure (IOP) but also has a safer 
cardiovascular profile than Timolol (27) because unlike Timolol, Adaprolol did not reduce 
the systolic blood pressure [24]. 
Glucocorticoid Soft Drugs: Ophthalmic Therapeutics 
Along the line of soft -blockers, development of soft anti-inflammatory glucocorticoids 
represents a promising and successful ophthalmic drug design area initiated by Bodor and 
his colleagues [24,26]. Inflammation in the eye could result from surgery, injury, infection, 
conjunctivitis, or uvitis-conditions that can cause severe discomfort even leading to loss of 
vision. As mentioned earlier, topical glucocorticoids represent an important class of 
molecules to treat ocular inflammations and allergies as they are the most effective anti-
inflammatory compounds offering the broadest range of treatment. However a number of 
contradictions limit their usefulness severely [12]. In addition to the general systemic side 
effects or adverse drug reactions (ADRs) associated with these glucocorticoids, they also 
cause several ocular complications such as IOP-elevation resulting steroid- induced 
glaucoma, induction of cataract formation and other secondary complications [12, 71]. In 
this context design of soft anti-inflammatory glucocorticoids has been one of the most active 
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and productive fields of soft drug design. Ophthalmic use of glucocorticoids usually causes 
increased intraocular pressure (IOP) as a result of increased resistance to aqueous humour 
outflow. The design of soft anti-inflammatory glucocorticoids has been one of the most 
important and most successful areas of Soft Drug design. Although the soft nature of such 
drugs are mainly associated with fast hydrolytic degradation, in fact it is not necessarily be 
so as Bodor and his co-workers suggested [24].Too much rapid hydrolysis may in fact result 
in weak activity. The desired increase of therapeutic index can be obtained only if the drug 
is sufficiently stable to reach the receptor sites at the target organ to produce the desired 
effect, but the free, non-protein-bound drug undergoes facile hydrolysis to avoid undesired 
systemic side effects. Therefore to develop a soft drug and hence separating successfully the 
desired local activity from systemic toxicity, an adequate balance between intrinsic activity, 
solubility/lipophilicity, tissue distribution, protein binding and rate of metabolic 
deactivation have to be achieved. In the case of slow, sustained release to the general 
circulatory system from delivery site, even a relatively slow hydrolysis could result in a very 
low, almost steady-state systemic concentration [24]. Based on these concepts of eye-
targeting chemical delivery systems (CDSs) and retrometabolic drug design approaches, 
Bodor and his group was successful in developing glucocorticoid soft drugs for ophthalmic 
therapeutics having potential market value.  
First Generation Cortienic Acid (39)-based Glucocorticoid Soft Drugs: Loteprednol Etabonate (41) 
and its Analogs (42): 
Synthesis of Dug molecules and Structure-Activity Studies: 
As already mentioned, Bodor and his colleagues [24, 26] have applied retrometabolic drug 
design approach to a variety of therapeutic agents such as - blockers, antimicrobials, 
analgesics, and acetyl cholinesterase (ACE) inhibitors and were successful in developing 
retrometabolically designed molecules reaching towards market application. They had 
designed a number of analogs starting with 1-cortienic acid (40), the primary metabolite of 
prednisolone that lacks corticosteroid activity [25]. Hydrocortisone can undergo a variety of 
oxidative and reductive metabolic conversions [72] by local esterases within the system. Thus 
oxidation of its dihydroxyacetone side chain leads to the formation of cortienic acid via 21-
dehydrocortisol (21-aldehyde) and cortisolic acid (21-acid) [Figure 5]. Cortienic acid (39) is 
an ideal lead molecule for the inactive metabolite soft drug (SD) approaches because it is 
lack of corticosteroid activity and therefore is major metabolite excreted in human urine. To 
get the new lead compounds, the pharmacophore moieties of the 17-hydroxyl and 17- 
carboxy substituents of the lead compound had to be restored by suitable 
isosteric/isoelectronic substitution containing esters or other types of functions that could 
restore the anti-inflammatory potency of the original corticosteroid while at the same time 
incorporating hydrolytic features to ensure metabolism. Other structural considerations 
included the presence or absence of double bond at C-1 position, presence of 6 or 9 
fluorine, and 16 & 16 –methyl group (Figure 6). More than hundred possible drug 
molecules were synthesized and tested in pre-clinical anti-inflammatory models [5]. 
Structure-activity studies by Bodor and his group [24] of these molecules have confirmed 
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that the best substituent for maximal therapeutic activity included a haloester at 17 
position and a carbonate or ether moiety at 17 position. Incorporation of 17 carbonates 
or ether was preferred over 17 esters to increase stability and to prevent potential 
formation of mixed anhydrides by reaction of a 17 ester with a 17 acid functionality and 
subsequent potential for lens protein binding leading to steroid- induced cataract formation. 
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Figure 5. Oxidative metabolism of hydrocortisone by local esterases into C-21 Aldehyde and C-21 Acid 
(Cortisolic Acid) 
Therefore in addition to the C-20 ketone functionality of prednisolone being replaced to 
eliminate the possibility of Schiff base intermediates, other chemical features associated with 
cataracterogenesis were also eliminated by the proposed design. The carbonates were 
expected to be less reactive than the corresponding esters due to the lower electrophilicity of 
the carbonyl carbon [24].  
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Figure 6. Design of 1st Generation Cortienic acid-based Glucocorticoid Soft Drugs (42) with their 
Glucocorticoid Soft Drug representative Loteprednol Etabonate (LE)(41) 
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Loteprednol Etabonate (LE) namely chloromethyl- 17-[(ethoxycarbonyl) oxy]-11-hydroxy-
3-oxoandrosta-1, 4-diene-17 -carboxylate (41), was the most promising drug candidate 
among the various cortienic acid-based derivatives synthesized by Bodor and his group 
(Figure 6)]. In Loteprednol Elaborate (41), a metabolically labile ester function occupies 17 
- position, while a stable carbonate group occupies 17-position. The ester is hydrolyzed to 
an inactive carboxylic acid, Δ1-cortienic acid etabonate (43), and then into Δ1-cortienic acid 
(40) in biological systems after exerting the desired therapeutic effect, thereby minimizing 
the likelihood of toxicity [Figure 7]. As a result of the predictable conversion of Loteprednol 
Etabonate into an inactive metabolite in the eye following topical administration, this 
glucocorticoid has a low propensity for undesirable toxicity while possessing increased anti-
inflammatory activity. In fact Loteprednol Etabonate (41) has been found to be 1.5 times 
more potent than the parent anti-inflammatory agent dexamethasone [24].  
Loteprednol Etabonate (41) and its Clinical Investigations in Ophthalmic Therapeutics: 
Clinical study confirmed that Loteprednol Etabonate and some of the other soft 
glucocorticoids synthesized, provided a significant improvement of the therapeutic index, 
determined as the ratio between the anti-inflammatory activity and the thymus evolution 
activity [24]. In addition, binding studies using rat lung cytosolic corticosteroid receptors 
exhibited that the receptor binding affinity of LE and some of its analogs even exceeded that 
of the most potent glucocorticoids known[24]. Loteprednol Etabonate (41) is the one of the 
first-generation cortienic acid-based glucocorticoid soft drugs to get approved by Food and 
Drug Administration (FDA), USA for use in all inflammatory and allergy-related 
ophthalmic disorders, including inflammation after cataract surgery, uveitis, allergic 
conjunctivitis, and giant papillary conjunctivitis (GPC) [73-76]. Clinical tests on LE (41) by 
various groups of workers suggest it to be a potent glucocorticoid soft drug for ocular 
therapeutics. LE has also been selected for development as a potent glucocorticoid soft drug 
based on various considerations including the therapeutic index, availability, synthesis, and 
`softness’ (the rate and easiness of metabolic deactivation). LE is now the active ingredient 
of a number of ophthalmic preparations available in the market (Lotemax, Alrex, Zylet etc.) 
[73, 74, 76].  
Loteprednol Etabonate (41) has been found to be highly lipophilic which is 10 times greater 
than that of Dexamethasone (2), a characteristic that could increase its efficacy by enhancing 
penetration through biological membranes [24,26]. Competitive binding studies with rat 
lung type II GRs confirmed that binding affinity of LE was more than 4 times that of 
Dexamerhasone [77]. A vasoconstriction test in humans used to assess the bioavailability 
exhibited that LE could produce a blanching response similar to that of Betamethasone 17-
valerate (16) to confirm its good penetration properties and strong potency [11]. Bodor and 
his group, have reported the therapeutic index of LE having more than 20-fold better than 
that of other glucocorticoids including Hydrocortisone 17-butyrate (14), Betamethasone 
17-valerate (16) and Clobetasol 17-propionate (17) based on their cotton pellet glaucoma 
test and thymolysis potency [9]. LE (41) has been rightly selected on the basis of 
considerations including Therapeutic Index (TI) which is the ratio between the median toxic 
dose (TD50) and the median effective dose (ED50), availability, synthesis and the rate and 
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easiness of metabolic deactivation (Softness)[24]. In traditional glucocorticoids such as 
Hydrocortisone 17-butyrate (14), Betamethasone 17-valerate (16) and Clobetasol 17- 
propionate (17), efficacy and toxicity are closely correlated ( r2 =0.996) applying the 
relationship between the anti- inflammatory and thymus involution activities [24] 
determined in the cotton pellet granuloma test (Figure 8). In these glucocorticoids, the 
reported results [24] have shown that TI have been found to be almost similar regardless of 
their intrinsic activities; however glucocorticoid soft drug Loteprednol Etabonate (41) owing 
to its softness and improved toxicity profile, provides a significant improvement(24) (Table 
4).   
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Figure 7. Metabolism of Loteprednol Etabonate (41) to 1-Cortienic acid etabonate (43) and then to 1-
Cortienic acid(40). 
Loteprednol Etabonate (LE) is predictably metabolized by local esterases into its inactive 
metabolite Δ1-cortienic acid (40) which has been confirmed through animal studies [20]. 
Clinical studies by Druzgala et al [78] have confirmed that the highest concentration of LE 
was found in cornea, followed by the iris/ciliary body and aqueous humour. The cornea also 
showed the highest ratio of metabolite to Loteprednol Etabonate (41), indicating that the 
cornea was the prime site of metabolism, while aqueous humour concentrations of LE were 
nearly 100-fold lower. This finding suggested that Loteprednol Etabonate may exert a 
decreased IOP effect as compared to other glucocorticoids [78]. Further a comparison of the 
IOP-elevating activity of Loteprednol Etabonate with that of Dexamethasone (2) in rabbits 
confirmed a lack of IOP effect with LE [79, 80]. LE was found to have a terminal half- life 
(t1/2) of 2.8 hrs in dogs following intravenous administration [81]. Further when absorbed 
systemically, LE was found to be metabolized to 1-cortienic acid etabonate (43) and then to 
1-cortienic acid (40) (Figure 7) and have been found to be eliminated rapidly through the 
bile and urine [26, 81, 82]. So far numerous preclinical tests were carried out on Loteprednol 
Etabonate (41) including more recent ones by Comstock and DeCory [20, 83]. Most of these 
clinical studies have confirmed that Loteprednol Etabonate achieves the required balance 
between the solubility/lipophilicity, ocular tissue distribution, receptor binding, and 
subsequent rate of metabolic deactivation as have been outlined by Bodor when he 
conceptualized for the first time the retrometabolic drug design. 
Since the design of this glucocorticoid soft drug LE by Bodor and his group, various 
ophthalmic suspension formulation of LE viz., a 0.2% suspension, a 0.5% suspension and a 
combination suspension of LE 0.5% plus tobramycin 0.3%, have been developed and clinically 
tested in various ocular inflammatory conditions and postoperative ocular inflammation.  
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Figure 8. Literature reported [24] graph showing the relationship between the Efficacy [log 1/ED50 
(μg/pellet)] and Toxicity [log 1/TD50 (μg/pellet) of Hydrocortisone-17 α-Butyrate (14: 0.1%), 
Betamethasone-17 α-Valerate (16: 0.12%), Clobetasone-17 α-Propionate (17: 0.1%) and Loteprednol 
Etabonate (41: 0.1%). Relative TI being computed with Betamethasone-17 α-Valerate (16) as reference. 
 
Glucocorticoids 
Therapeutic Index (TI) 
TD50/ED50 
Relative Therapeutic 
Index  
(Rel TI) TI/TIBMV 
Loteprednol Etabonate (41) 56.2 22.5 
Clobetasone-17-Propionate (17) 3.8 1.5 
Hydrocortisone-17 -Butyrate (14) 3.1 1.3 
Betamethasone-17 -Valerate 
(BMV: 16) 
2.5 1.0 
Table 4. Literature reported Therapeutic Index (TI) and Relative Therapeutic Index (Rel. TI) of some 
glucocorticoids and Loteprednol Etabonate (41). Relative Therapeutic Index was computed with 
Betamethasone-17 -Valerate (BMV)(16) as the reference. 
Ocular diseases against which LE formulations were clinically tested included Giant 
Papillary Conjunctivitis, Prophylaxis of Seasonal Allergic Conjunctivitis, Seasonal Allergic 
Conjunctivitis, Anterior Uveitis, Blepharokerato Conjunctivitis, and Keratoconjunctivitis 
sicca etc. All these studies confirmed the clinical anti-inflammatory potency of LE and lack 
of significant IOP after its use [20]. Again two identical placebo-controlled trials examined 
the safety and efficacy of LE in treating post operative inflammation following cataract 
surgery with intraocular lens implantation [92]. Ilyas et al [93] have studied the long term 
safety of LE 0.2% by conducting a retrospective review of more than 350 seasonal and 
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perennial conjunctivitis patients who used LE 0.2% on a daily basis for extended periods of 
time. The results showed the absence of significant ADRs as there were no reports of 
posterior subcapsular opacification with quite insignificant IOP in most of the patients. In 
fact there was no observation of IOP elevation greater than 4mm Hg over base line at any 
period of time.  
Besides, safety and efficacy of LE ophthalmic ointment 0.5% in the treatment of 
inflammation and pain following cataract surgery was studied in two randomized, 
multicentre, double-masked, parallel group, vehicle-controlled studies [20]. A very fewer LE 
ointment-treated patients needed rescue medication and most of them did not showed any 
ocular adverse event. Clinical trials on gel formulation of LE in treatment of ocular 
inflammation and pain after cataract surgery have been taken up more recently [20]. It is 
because of the high lipophilic nature of LE, gel formulation could provide improved 
product homogeneity over a suspension formulation to enhance its more consistent clinical 
response. 
LE has been designed by Bodor and his group with a C-20 ester rather than a C-20 ketone 
and so LE is unable to form covalent adduct with lens protein, the main reason behind 
steroid-induced cataract formation as discussed earlier. Global market research indicates 
that an estimated more than 20 million LE units have been distributed globally. Clinical 
studies suggest the rapid metabolism of LE into inactive metabolites in conjunction with the 
lack of C-20 carbonyl functionality have resulted in LE – to become a unique glucocorticoid 
soft drug with significantly less, if any, potential for promoting steroid-induced cataract 
formation.[20]. LE has now been proved as a safe and effective treatment for contact lens-
associated GPC, seasonal allergic conjunctivitis, postoperative inflammation or uveitis. 
Retrospective study established that even long time (>1 year) use of LE caused no reported 
adverse effects. .  
Synthesis of the Side Chain of Loteprednol Etabonate (41) directly from 20-Oxopregnane (44) to 
furnish an Analog (45) of LE: 
Based on promising results from animal studies, further clinical trials on Loteprednol 
Etabonate (41) are also going on for a safer treatment of gastrointestinal inflammation and 
other diseases such as asthma, rhinitis, and dermatological problems [76,82,84-86]. Success 
story of this retrometabolically designed glucocorticoid soft drug Loteprednol Etabonate has 
drawn attention to pharmaceutical industries as well as people working in steroid field 
worldwide. The authors of this chapter [87], recently, have reported a facile synthesis of the 
side chain of this potent ocular glucocorticoid soft drug, starting directly from 20-
oxopregnanes, viz., 3β-acetoxy-pregn-5(6),16(17)-diene-20-one (16- dehydropregnenolone 
acetate i.e. 16-DPA) (44)- a potent steroid drug intermediate, utilizing their recently 
developed metal mediated halogenation technique as a key reaction [88,89 ] to furnish the 
final product –an analog (45) of Loteprednol Etabonate (41) with the requisite side chain 
[Scheme 1]. 
The present methodology paves a useful and productive way to construct the side chain of 
this important glucocorticoid soft drug directly from 20-oxopregnanes via its C-21 
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functionalization in much simpler and easier way with their newly developed metal 
mediated halogenation technique, which avoids application of harsh and tedious reaction 
conditions associated with this conversion [90, 91]. 
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Scheme 1. Reagents and conditions: (i) H2,Pd-C, 95% (ii) MnO2-TMSCl/AcCl-AcOH, 81% (iii) 3% KOH, 
MeOH-H2O, 75% (iv) LiAlH4,THF, 88% (v) CAN, AcOH, 75% (vi) m-CPBA, CHCl3, 62% (vii) 
H2SO4,acetone-H2O, 48% (viii) Jones reagent, 57% (ix) OsO4 – H2O2, rt., 50% (x) NaIO4 , Ethyl 
chloroformate, 70% xi) Chloromethyl iodide, 75% .  
Second –generation Cortienic Acid (39)-based Glucocorticoid soft drugs: Etiprednol dicloacetate (46) 
and its Analogs (47): 
Synthesis of Drug molecules and Structure-Activity Studies: 
Based on their retrometabolic drug design approach, Nicholas Bodor [94] have more 
recently introduced another new class of soft glucocorticoids with 17-dicloroester 
substituent. These are now known as the second generation soft glucocorticoids (Figure 9). 
This is said to be a unique design as no known glucocorticoid has been found to contain a 
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halogen substituent at the 17 position. Nevertheless, the pharmacophore portions of these 
second- generation cortienic acid-based soft glucocorticoids, having the halogen atoms at 
17 position, can be positioned so as to provide excellent overlap with those of the 
traditional glucocorticoids [24, 95]. It has been conceived the idea that dichlorinated 
substituents seem required for activity and sufficiently soft nature. Molecular configuration 
suggests that with dicholrinated substituents, one of the chlorine atom would necessarily 
point in the direction needed for pharmacophore overlap, whereas with monochlorinated 
substituents, steric hindrance might force the lone chlorine atom to point away from this 
desired direction. Secondly experimentally it has been found that as compared with the 
unsubstituted ester, dichloro substituents could cause ~20 fold increase in the second-order 
rate constant kcat/KM of enzymatic hydrolysis in acetate esters, on the other hand monochloro 
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Figure 9. Design of 2nd Generation Cortienic Acid-based Soft Glucocorticoids Soft Drugs (47) and their 
Glucocorticoid Soft Drug representative Etiprednol Dicloacetate (ED)(46) 
substituent did not cause any change [96]. Unlike first generation soft glucocorticoids, in the 
second generation of this soft steroid series, hydrolysis primarily cleaves the 17- ester 
group and not the 17-ester group. The corresponding metabolites are also not active. From 
large no of compounds synthesized in this series, Etiprednol Dicloacetate (ED) (46) had been 
selected for development as a potent ocular glucocorticoid soft drug [24].  
Etiprednol Dicloacetate (46) and its Clinical Investigations in Ophthalmic Therapeutics: 
In animal and in human clinical trials, in accordance with its soft nature, Etiprednol 
Dicloacetate (46) was found to have low systemic toxicity [94, 97-99]. Etiprednol Dicloacetate 
had also shown better receptor binding capacity than Loteprednol Etabonate and was found 
to be more effective than Budesonide (3) in various asthma models [24]. Further No 
Observable Adverse Effect Level (NOAEL) of ED after oral administration for 28 days was 
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found to be 2mg/kg in rats and dogs, and about 40 times higher than that of Budesonide 
[97]. 
The comparison of the transrepressing and transactivating activity of Etiprednol 
Dicolacetate (46) and Budesonide(3) were done by measuring their inhibition in 
interleukin(IL)-1 production of a simulated human monocyte cell line and by evaluating 
glucocorticoid-induced increase in the activity of tyrosine-amino-transferase ( TAT) of a rat 
hepatoma cell line respectively [99] and the measured activities were expressed relative to 
Dexamethasone (2) From the results it was found that ED (46) possesses less transactivating 
activity with a preserved transrepressing acivity, and hence ED is to be called as a 
dissociated glucocorticoid. Dissociation of transactivating ( carbohydrate metabolism 
altering) and transrepressing ( anti-inflammatory) activity found in Etiprednol 
Dicloacetate(ED) is a fruitful advantage in subsequent help in separating the most beneficial 
anti-inflammatory activity from the undesired side effects or adverse drug reactions 
(ADRs).A comparison of transrepression ( anti-inflammatory effect) and transactivation 
(carbohydrate metabolism altering) effects of dexamethasone (2), used as 100% reference, 
Budesonide (3) and Etiprenol Dicloacette (46) determined on an average of two experiments 
for concentrations of 10 -7 (98) is depicted in Figure 10 [24]. Hence this productive effort in 
developing dissociated glucocorticoids can be termed as one of the novel and sought after 
mechanistic approaches towards the development of newer glucocorticoid soft drugs [24, 
100,101].  
 
Figure 10. Literature reported [24] tentative comparison of transrepression (anti-inflammatory effect) 
and transactivation (carbohydrate metabolism altering) effects of dexamethasone (2)(used as 100% 
reference), Budesonide (3) and Etiprednol Dicloacetate (46) 
3. Conclusion 
Since the introduction of glucocorticoids in drug industry more than a half century ago, new 
series of glucocorticoids have been introduced for site specificity as well as for minimizing 
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systemic side effects. At the initial stage, several new generation glucocorticoids were 
developed using prodrug design approach involving changes or modifications made in 
glucocorticoid molecules introducing specific substituents at various specific positions of the 
basic glucocorticoid skeletons to obtain better skin penetration, slower enzyme degradation 
and greater affinity for the cytosol receptor. The term prodrug refers to a pharmacologically 
inactive molecule that is converted to an active drug by metabolic biotransformations that 
may occur prior, during or after adsorption or at specific target sites within the body. This 
approach has given several potent new generation glucocorticoids such as Budesonide (3), 
17-Prednicarbate (9), Fluticasone propionate (11), Methyl prednisolone aceponate (5), 
Beclomethasone (7) etc towards successful treatment of plethora of diseases including 
psoriasis, allergies, asthma, rheumatoid arthritis and lupus, with significantly minimized 
systemic side effects. However, all these old and new generation glucocorticoids are 
effective in reducing anterior segment inflammation only and not suitable for ophthalmic 
therapeutics as they are found to be associated with Adverse Drug Reactions (ADRs) 
including elevation of Intraocular Pressure (IOP) and steroid-induced cataract formation in 
case of ophthalmic therapeutics as they were not designed for ocular treatment. Successful 
eye-specific therapeutic agents can only be achieved by suitable drug-design approaches 
which thoroughly can integrate the specific pharmacological, metabolic, and targeting 
requirements of ophthalmic drugs. Chemical Delivery Systems (CDSs) and Retrometabolic 
Soft Drug Design approaches initiated by Prof.Nicholas Bodor and his group at the Center 
for Drug Discovery, University of Florida, Health Science Center, USA, are found to be quite 
successful with a major break through for this purpose providing flexible and generally 
applicable solutions. Their potential is indeed well illustrated by the results obtained with a 
number of soft -blockers and glucocorticoid soft drugs designed within this framework 
towards ophthalmic therapeutics. Soft -blockers, viz., Betaxoxime (29a), Adaprolol (33) and 
Glucocorticoid Soft drugs viz.,, Loteprednol Etabonate (41) and Etiprednol Dicloacetate (46) 
are some of the soft drugs developed by this retrometabolic drug design approach which 
have already reached the clinical development phase in various ophthalmic areas and one of 
them Loteprednol Etabonate (LE) is already being in the market as a promising 
glucocorticoid soft drug in ophthalmic therapeutics. Not only that, based on clinical results 
from animal studies, LE now also finds place in safer treatment of gastrointestinal 
inflammations and other diseases such as asthma, rhinitis and dermatological problems. 
Moreover dissociation of transactivating and transrepressing activity found in the second 
generation glucocorticoid soft drug, viz., Etiprednol Dicloacetate (ED) could open up a 
novel and promising mechanistic pathways towards the development of more and more 
potent glucocorticoid soft drugs in future. 
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